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Edited by Beat ImhofAbstract ADAM12, a disintegrin and metalloprotease, has
been demonstrated to be upregulated in human malignant tumors
and to accelerate the malignant phenotype in a mouse model for
breast cancer. ADAM12 is a substrate for b1 integrins and may
aﬀect tumor and stromal cell behavior through its binding to b1
integrins. Here, we report that cells deﬁcient in b1 integrin or
overexpressing b3 integrin can bind to recombinant full-length
human ADAM12 via b3 integrin. Furthermore, cell binding to
ADAM12 via b3 integrin results in the formation of focal adhe-
sions, which are not formed upon b1 integrin-mediated cell
attachment. We also show that RhoA is involved in b3 inte-
grin-mediated focal adhesion formation.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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RhoA; Cancer1. Introduction
Cell–cell and cell–substrate adhesion are important determi-
nants of cell behavior. A thorough understanding of the
molecular mechanisms of cell adhesion would allow modula-
tion of such processes as embryonic development, the growth
and spread of cancer, and degenerative diseases including Alz-
heimers disease and muscular dystrophy. We and others have
shown that ADAM12, a disintegrin and metalloprotease, is
highly expressed in human carcinomas, including colon and
breast carcinoma [1–4], and that levels of ADAM12 excreted
in the urine correlate with tumor grade and progression [5].
Furthermore, Kodama et al. [6] demonstrated that ADAM12
is highly expressed in human glioblastomas. Our recent data
using a mouse model of breast carcinoma suggest that
ADAM12 induces more aggressive tumor growth [3]. Collec-*Corresponding author. Fax: +45 3532 6081.
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e Federtively, these ﬁndings suggest a role for ADAM12 in tumor cell
behavior, such as invasion and metastasis.
ADAM12 belongs to a family of cell surface proteins having
proteolytic, cell adhesion, and signalling activities [7,8]. These
multidomain and multifunctional proteins are composed of
pro-, metalloprotease, disintegrin-like, cysteine-rich, epidermal
growth factor-like repeat, transmembrane, and cytoplasmic
tail domains. Several diﬀerent ADAMs, including ADAM 2,
9, 12, 15, and 23, have been shown to support cell attachment
[9,10]. Cell binding to the Escherichia coli-produced recombi-
nant ADAM15 and ADAM12 disintegrins domain is mediated
exclusively through a9b1 integrin in a RGD-independent man-
ner [11]. Cells can also bind to full-length human ADAM12 via
integrins with other a subunits, such as a3 and a6 if, as in most
carcinoma cells, a9b1 integrin is not expressed [12] . In the
present study, we report that, in cells deﬁcient in all b1 integrin
expression or in cells that express b3 integrins in high amounts
by transfection, ADAM12 can bind to b3 integrins. Notably
engagement of b3 integrins by ADAM12 triggers RhoA-
dependent stress ﬁber and focal adhesion formation. Further-
more, the b3 integrin binding epitope in ADAM12 is located in
the disintegrin domain.2. Materials and methods
2.1. Cell lines
Human MDA-MB-231 breast carcinoma (HTB26) and MG63 hu-
man osteosarcoma (CRL-1427) were obtained from the American
Type Culture Collection (Manassas, VA, USA). Other cell lines in-
cluded: bovine capillary endothelial cells (BCE) were kindly provided
by Catherine E. Butterﬁeld and Marsha Moses (Harvard Medical
School and Childrens Hospital, Boston, USA). Murine GD25 ﬁbro-
blastic cells deﬁcient in b1 integrin, GD25 cells which had been trans-
fected to express a functionally active b1A integrin (GD25-b1A) [13],
chondroblasts deﬁcient in b1 integrin (b1/) or not (b1+/+) [14,15],
and Chinese hamster ovary (CHO-K1) cells which had been transfec-
ted with human b3 integrin (b3-CHO) or vector only (pBJ-1-CHO)
[16].2.2. Antibodies and reagents
The full-length secreted form of ADAM12 (ADAM12-S), a trun-
cated form consisting of the prodomain, the metalloprotease do-
main, and the disintegrin domain (A12-PMD), a truncated form
consisting of the disintegrin- and the cysteine-rich, including the
EGF-like domain (A12-DC) were produced in EBNA-293 cells
and puriﬁed as described [12]. Recombinant disintegrin domain
(rADAM12-dis) and cysteine-rich domains of ADAM12ation of European Biochemical Societies.
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described [17]. The b3 integrin function-blocking antibodies c7E3
(ReoPro) and 2C9.G2 were obtained from Eli Lilly (Lyngby,
Denmark) and BD Pharmingen (San Diego, CA, USA), respec-
tively. The b1 integrin function-blocking monoclonal antibody,
AIIB2, was provided by the Developmental Studies Hybridoma
Bank maintained by the Department of Biological Sciences, Univer-
sity of Iowa, IA, USA. The antibodies AIIB2 and LM609 (Chem-
icon, Temecula, CA, USA), were used to detect surface expressing
of b1 and b3 integrin in MDA-MB-231, MG63, and BCE, while
7E2 (gift from Rudy Juliano, University of North Carolina,
USA) and c7E3 were used for CHO-K1 and b3-CHO cells.
Tetramethylrhodamine isothiocyanate (TRITC)-phalloidin and
Alexa-546-conjugated goat-anti mouse secondary antibody were ob-
tained from Molecular Probes (Leiden, The Netherlands). Monoclo-
nal antibodies to vinculin were kindly provided by M. Glukhova,
Institut Curie, Paris, France or obtained from Sigma–Aldrich
(Clone hVIN-1; Brøndby, Denmark). Human ﬁbronectin and ﬁbrin-
ogen were obtained from Calbiochem–Novachem (Bad Soden/TS,
Germany) and EHS-laminin from Invitrogen (Ta˚strup, Denmark).
Western blot to document expression of b1 and b3 integrin was
performed using JB1A and B3A antibodies (Chemicon), respec-
tively. All other standard chemicals, including heparin and the
synthetic peptides GRDGS and SDGRG, were purchased from
Sigma–Aldrich.2.3. Cell attachment assays, morphological and immunochemical
analysis
The cell attachment assay was performed as described previously
[12]. Mn2+ was added, when indicated. In some experiments, the
cells were co-transfected with a dominant negative construct of
RhoA (N19RhoA; kindly provided by Dr. Allan Hall, University
College, London, UK) and EGFP vector or EGFP alone as
previously described [18] or preincubated with heparin (10–40 lg/
ml), or ROCK (the Rho kinase)-speciﬁc inhibitor Y-27632 (10 lM)
obtained from Calbiochem–Novachem or integrin function-blockingFig. 1. b1 integrin-speciﬁc adhesion to full-length human ADAM12. (A) FA
MB-231 and MG63 cells. BCE cells served as a control for b3 integrin exp
respectively. (B) Western blot of total cell lysates demonstrating expression o
MB-231 and MG63 cells attached to full-length human ADAM12 and att
blocking monoclonal antibody AIIB2 but not by the b3 integrin function b
attachment.antibodies (10 lg/ml) or synthetic peptides (0.5 mM) for 20–30 min.
FACS analysis, Western blot, morphological analysis, F-actin
staining, and immunostainings were performed as described
[12,14].3. Results and discussion
3.1. b3 integrin is an alternative ADAM12 adhesion receptor
We previously reported that full-length ADAM12 supports
cell attachment of various human tumor cell lines in a b1
integrin-dependent manner. This conclusion was based on
the ﬁnding that b1 integrin function-blocking antibodies
completely inhibited tumor cell attachment to ADAM12
[12]. The small amounts of b3 integrin expressed at the cell
surface of these tumor cells did not signiﬁcantly promote
adhesion to ADAM12, and no inhibition of cell attachment
was obtained using a b3 integrin function blocking monoclo-
nal antibody (c7E3) (Fig. 1). We subsequently tested the
ability of b1 integrin-deﬁcient murine chondroblasts and b1
integrin-deﬁcient murine GD25 ﬁbroblastic cells to attach
to ADAM12 and as a control EHS-laminin and ﬁbronectin.
Unexpectedly, in ADAM12-cell attachment assays, both
types of b1 integrin-deﬁcient cells attached to ADAM12
equally well as their b1 integrin-expressing counterparts
(Fig. 2A and B).
This ﬁnding raised the question of which receptor(s) the cells
use to bind to ADAM12 in the absence of b1 integrin. Because
it has been previously shown that avb3 integrin is present in
high amounts and is functionally active in forming focal con-CS analysis demonstrating b1 and b3 integrin at the surface of MDA-
ression. The antibodies AIIB2 and LM609 detect b1 and b3 integrin,
f b1 and b3 integrin. Actin were used as a loading control (C) MDA-
achment was almost completely inhibited by the b1 integrin function
locking monoclonal antibody c7E3. Control IgG had no eﬀect on cell
Fig. 2. b1 integrin deﬁcient cells use b3 integrin to bind to full-length human ADAM12. (A,B) Chondroblasts or GD25 ﬁbroblasts were plated in 96-
well plates coated with full-length human ADAM12, EHS-laminin, or ﬁbronectin (FN). Cells were allowed to attach for one hour, after which they
were ﬁxed and stained with crystal violet. The number of attached cells was quantiﬁed by measuring absorbance at 590 nm. (C,D) Chondroblasts
b1/ or GD25 cells were pretreated with function-blocking b3 integrin antibody (2C9.G2) for 30 min and examined as described for (A,B). (D)
GD25 cell attachment on ADAM12 (A12), rADAM12-cys (rA12-cys) and rADAM12-dis (rA12-dis) in the presence or absence of heparin. Results in
(A,D) are presented as means ± standard deviation (S.D.). Each assay point was derived from three to six separate wells and repeated at least three
times.
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hypothesized that attachment to ADAM12 by these b1 inte-
grin-deﬁcient cells could be mediated through b3 integrin. In
support of this hypothesis, we found that a b3 integrin func-
tion-blocking monoclonal antibody (2C9.G2) signiﬁcantly
inhibited attachment of both b1 integrin-deﬁcient GD25 ﬁbro-
blastic cells and b1 integrin-deﬁcient chondroblasts to full-
length ADAM12 (Fig. 2C). In contrast, these antibodies only
slightly inhibited attachment of b1 integrin expressing
GD25b1A or b1 integrin expressing chondroblasts to full-
length ADAM12 (not shown). Since we have previously
demonstrated that syndecans are the primary receptor for
the cysteine-rich domain of ADAM12 [2,14], we tested whether
heparin had an eﬀect on GD25 cell attachment to full-length
ADAM12. However, as demonstrated in Fig. 2D, heparin
had no eﬀect on GD25 cell attachment to full-length
ADAM12, while as expected signiﬁcantly inhibited the adhe-
sion to the recombinant cysteine-rich domain of ADAM12.
Furthermore, these GD25 cells did not attach to the recombi-
nant disintegrin domain of ADAM12, most likely as previ-
ously described [11,12] binding to this fragment requires a9
integrin (Fig. 2D).
We subsequently used b3-CHO cells, which express signif-
icant amounts of human b3 integrin relative to control CHO
cells, which express little or no endogenous integrin b3, in
ADAM12-cell attachment assays. By FACS analysis, the
expression of cell surface expression b1 integrin in b3-CHO
cells was found to be comparable to that of the CHO-K1
cells (Fig. 3A). b3-CHO cells attached well to ADAM12,
and a b3 integrin function-blocking antibody (c7E3) com-
pletely inhibited cell adhesion to ADAM12 and as a controlto ﬁbrinogen (Fig. 3B). The adhesion assays were performed
in the absence of Mn2+ demonstrating that b3 integrin bind-
ing to full-length ADAM12 did not require exogenous inte-
grin activators. b3-CHO cells spread and formed stress ﬁbers
in response to full-length ADAM12. Heparin had no eﬀect
on either cell attachment, spreading or stress ﬁber formation
of b3-CHO cells (Fig. 3C), indicating that syndecans were
not directly facilitating cell adhesion or cell spreading of
the cells. Based on the ﬁnding demonstrated in Fig. 3D that
ADAM12 fragments (A12-PMD and A12-DC) also sup-
ported b3-CHO cells adhesion, that could be inhibited by
b3 integrin function-blocking antibody (c7E3) but not by
heparin, we furthermore suggest that the binding site resides
in the disintegrin domain. Interestingly, b3-CHO cells did
not attach to the recombinant disintegrin domain (Fig. 3D)
produced by E. coli, suggesting that the b3 integrin binding
epitope in ADAM12 is conformation-dependent. Although
ADAM12 does not harbor a RGD-sequence in the disinte-
grin domain, a synthetic GRGDS-peptide completely inhib-
ited attachment of b3-CHO cells and GD25 to full-length
ADAM12, whereas the scramble SDGRG-peptide did not
(Fig. 3E). These data are consistent with the previously pub-
lished role of RGD-peptides which have an inhibitory eﬀect
for several other avb3 integrin ligands lacking the RGD-se-
quence [19–22]. Further studies are needed to reﬁne the b3
integrin binding epitope in the disintegrin domain of
ADAM12.
These results demonstrate that b3 integrin can substitute for
b1 integrin and mediate cell attachment in GD25 and chondro-
blast cells deﬁcient in all b1 integrin expression. Cells also use b3
integrin to bind to ADAM12 if overexpressed by transfection,
Fig. 3. If overexpressed, b3 integrin can act as an ADAM12 adhesion receptor. (A) FACS analysis demonstrating b1 and b3 integrin on the surface
of CHO-K1 and b3-CHO cells. Red lines represent control IgG and the black lines represent the integrins. (B) b3-CHO cells were treated or not with
c7E3 antibody for 30 min, plated in 96-well plates coated with full-length human ADAM12 (A12) or as a control ﬁbrinogen (Fg). Cells were allowed
to attach for one hour, after which they were ﬁxed and stained with crystal violet. The number of attached cells was quantiﬁed by measuring
absorbance at 590 nm. (C) b3-CHO cells were pretreated or not with heparin for 30 min, plated on culture dishes coated with ADAM12 and allowed
to adhere for three hours, then ﬁxed and photographed or stained with TRITC-phalloidin (to detect F-actin). (D) b3-CHO cells were treated or not
with c7E3 antibody or heparin for 30 min, plated in 96-well plates coated with full-length human ADAM12 (A12), a fragment containing the
prodomain, the metalloprotease domain, and the disintegrin domain (A12-PMD), a fragment containing the disintegrin, the cysteine-rich, and the
EGF-like domains (A12-DC), or with the recombinant disintegrin domain (rA12-dis). Cells were allowed to attach for one hour and examined as
described in (B). (E) Cells were pretreated or not with GRGDS peptide or the control SDGRG peptide for 15 min, plated on A12, Fg, or ﬁbronectin
(FN) and analysed as described in (B). Results in (B, D, and E) are presented as mean ± standard deviation (S.D.). Each assay point was derived
from three to six separate wells and repeated at least three times.
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the activity of b1 integrin is reduced by function-blocking anti-
bodies in b1 integrin-expressing human tumor cells. These re-sults also conﬁrm that full-length ADAM12 – at least in the
tumor cell repertoire we tested in our laboratory [12] – primarily
initiates a b1-dependent downstream signalling pathway.
Fig. 4. b3 integrin mediates formation of focal adhesions on
ADAM12. (A) pBJ-1-CHO or b3-CHO cells or (B and C) GD25-
b1A or GD25 cells were plated on dishes coated with full-length
ADAM12 or ﬁbronectin (FN). Cells were allowed to attach for three
hours, then ﬁxed and stained for the presence of focal adhesions with
anti-vinculin monoclonal antibodies (A and B) or TRITC-phalloidin
(to detect F-actin) (C). Images are representative of at least three
independent experiments. (C) The percentage of focal adhesion
forming cells (from B) is presented as mean ± standard deviation
(S.D.).
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adhesion formation in response to ADAM12
Morphological analysis revealed that upon attachment to
ADAM12, mock-transfected CHO cells (pBJ-1-CHO) exhib-
ited limited cell spreading (Fig. 4A) and only upon addition
of exogenous integrin activator Mn2+ did full spreading oc-
cur (not shown), whereas b3-CHO cells spread spontane-
ously (Fig. 3B and 4A). pBJ-1-CHO and b3-CHO cells
were plated on ADAM12 or ﬁbronectin for three hours
and focal adhesion formation was analyzed by vinculin
immunostaining (Fig. 4A). pBJ-1-CHO cells did not formfocal adhesions on ADAM12, whereas they formed distinct
focal adhesions mostly at the periphery of the cells upon
attachment to ﬁbronectin. On the other hand, b3-CHO cells
spread and formed well-developed focal adhesions on both
ADAM12 and ﬁbronectin, and the focal adhesions/ﬁbrillar
adhesions were evenly distributed over the entire cell body
on cells plated on both ADAM12 and ﬁbronectin.
Furthermore, GD25 murine ﬁbroblastic cells exhibited focal
adhesion formation in response to ADAM12, whereas b1
integrin expressing GD25-b1A cells did not (Fig. 4B). The
number of focal adhesion-forming cells were estimated and
the diﬀerence was found to be statistically signiﬁcant
(P < 0.005, Students t-test) (Fig. 4B). In addition, GD25
(b1 integrin-deﬁcient) murine ﬁbroblastic cells exhibited
stress ﬁber formation in response to ADAM12, whereas
b1 integrin expressing GD25-b1A cells did not (Fig. 4C).
These results suggest that engagement of b3 integrin – but
not b1 integrin – in response to ADAM12 induces focal
adhesion and stress ﬁber formation.3.3. The small GTPase RhoA is involved downstream of
ADAM12/b3 integrin signaling
Recently, it was shown that b3 integrins can either activate
or inhibit RhoA activity in cells plated on ﬁbronectin, and that
RhoA dramatically aﬀects the ability of cells to organize their
cell–matrix adhesions [16,23]. We therefore tested whether the
Rho pathway is involved in b3 integrin-dependent focal adhe-
sion formation on ADAM12. We treated b3-CHO cells with
the Rho-kinase inhibitor Y-27632 for 30 min and subsequently
plated the cells on ADAM12 for three hours. The untreated
b3-CHO cells attached, spread, and formed well-developed
stress ﬁbers and focal adhesions (Fig. 5A). Treatment with
Y-27632 signiﬁcantly inhibited formation of these structures
in b3-CHO cells plated on ADAM12 (Fig. 5A). Furthermore,
to more directly examine the involvement of Rho, we transfec-
ted b3-CHO cells with a dominant negative N19RhoA con-
struct together with EGFP vector. EGFP vector transfection
alone served as a control. Transfection with the dominant neg-
ative RhoA, but not control vector, signiﬁcantly inhibited both
stress ﬁber (P < 0.0005, Students t-test) and focal adhesion
formation (P < 0.0005, Students t-test) in b3-CHO cells plated
on ADAM12 (Fig. 5B). These results suggest that the RhoA
operates downstream of ADAM12-induced b3 integrin-medi-
ated focal adhesion formation. Furthermore, the data support
the notion that the nature of the ligand binding to b1 or b3
integrins regulates the activity of Rho-GTPases and their eﬀec-
tor proteins.
In conclusion, our results demonstrate that, although cells
preferentially use b1 integrin to bind to full-length
ADAM12 as in previous studies [12], b3 integrin can substi-
tute for the absence of b1 integrins. However, cell binding
to ADAM12 via b3 integrin induces stress ﬁber and focal
adhesion formation through a signalling pathway that in-
volves RhoA while cell binding via b1 integrins does not.
Thus, cell binding to full-length recombinant ADAM12
initiates separate signaling pathways through b1 integrin
and b3 integrin. This study together with our recent
study on the binding of diﬀerent a integrins to full-length
human ADAM12 [12] might explain the diverse eﬀect of
ADAM12 observed on diﬀerent cell types in vitro and
in vivo [3,8].
Fig. 5. RhoA mediates b3-integrin/ADAM12-induced stress ﬁber and focal adhesion formation. (A) b3-CHO cells were pretreated with the Rho
kinase inhibitor Y-27632 for 30 min, then plated on dishes coated with full-length ADAM12 and allowed to attach for three hours. The cells were
ﬁxed and stained with TRITC-phalloidin (to detect F-actin) or anti-vinculin monoclonal antibodies. (B) b3-CHO cells were cotransfected with
dominant-negative N19RhoA and/or enhanced green ﬂuorescent protein expression vector. The cells were then plated on dishes coated with full-
length ADAM12 and allowed to attach. The cells were ﬁxed and stained for the presence of stress ﬁbers or focal adhesions, respectively. Between 50
and 100 transfected cells in three independent experiments were examined. Results are presented as % of the total number of transfected cells
(means ± S.D.) with stress ﬁbers (left panel) or focal adhesions (right panel), respectively.
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